Disease Organisations

Disorders Society

APARDO CONFERENCE

MALAYSIA

24-26 NOVEMBER, 2023

Venue: Pullman Kuala Lumpur City Centre, Malaysia

Agenda

DAY 0 : Friday, November 24 (4:30PM – 9:00PM MYT)

Time MYT	Program	Speaker(s)
4:30 – 5:30PM	APARDO Member Update Meeting	Dr. Durhane Wong-Rieger
6 :00– 9:00PM	Networking Dinner & Special Showcase	Malaysian Rare Disorders Society & Friends

DAY 1 : Saturday, November 25 (8:00AM – 6:45PM MYT)

Time MYT	Program	Speaker(s)
8:00 – 8:45AM	Registration	
8:45 – 9:00AM	Conference Welcome & Opening	Malaysian Rare Disorders Society
9:00 – 9:15AM	Welcome Remarks Theme: The Rare Disease Patient Journey Empowering the Patient from Diagnosis to Policy	Dr. Durhane Wong-Rieger (APARDO)
9:15 – 9:30AM	Opening Keynote: Optimizing Patient Journeys, a Malaysian Perspective	YBhg. Dato' Dr Azman bin Yacob (Director of Medical Development, Ministry of Health Malaysia)
9:30 – 9:40AM	Empowered Rare Disease Patient Advocacy	Ms. Nadiah Hanim Abdul Latif (MRDS)

Sponsored by:

AstraZeneca Janssen NOVARTIS Kyowa Kirin Roche Pfizer sanofi



Time MYT	Program	Speaker(s)
9:40 – 10:30AM Session 1	Large Group (45 min) An Ideal-but-Realistic Shared Vision of Asia-Pacific Rare Disease Network — 7 Years from Today 1. Why should governments invest in rare disease and what kinds of "Return on Investment" will be meaningful and be measured? 2. How will rare diseases be diagnosed and how will this look across the region? 3. How will optimized "shared-care" pathways be developed and put into practice across the region? 4. What does "good" access to treatment look like? What and how should essential drugs be available? How should innovative drugs be accessible and affordable? 5. What stakeholders will need to come together to build an AP Rare Disease Ecosystem and would effective partnerships look like? 6. What does good support care for individuals and families look like? 7. What are some "critical" rare disease policies to be adopted across the region? 8. How will we know the Network Vision is Working? Discussion (10 min) Should we (collectively) pursue this vision? Are these desired outcomes achievable? Who will benefit? What are facilitators and challenges?	Moderators: Ms. Monica Ferrie (Genetic Support Network of Victoria) Ms. Nadiah Hanim Abdul Latif (MRDS) Dr. Durhane Wong-Rieger (APARDO & Rare Disease International) Panelists: Dr. Carmencita Padilla (TBC) Dr. Duangrurdee Wattanasirichaigoon (Mahidol University & Thai Rare Disease Foundation) Dr. Fuu-Jen Tsai (Taiwan Human Genetics Society)(TBC) Dr. Thong Meow Keong (Pediatrics and Clinical Genetics, University of Malaya Medical Center, Kuala Lumpur, Malaysia) Ms. Preeya Singhnarula (Thai Rare Disease Foundation) Ms. Cynthia Magdaraog / Ms. Jane Francisco Kochis (Philippine Society for Orphan Disorders) Dr. Rachel Yang (China Alliance for Rare Diseases) Ms. Anne Sophie Chalandon (Sanofi) Mrs. Alexandra Heumber (RDI) Dr. Fariz Abdul Rani (Roche)
10:30 – 11:00AM	Morning Tea Break & Media Briefing	
11:00AM – 12:00PM Session 2	Collaborative Approach to Shorten Diagnostic Odyssey Applying "Lessons Learned" to "Challenges" Along Diagnostic Journey (60 min) • Family perspective –Lived experience of the journey to diagnosis – pain points along the way (10 min) • Network for Newborn Screening across 7,000 islands (15 min) • From Diagnosis to Specialized Care and Treatment (15 min) • Supporting the Family with Diagnosis (15 min) Discussion: How will AP Network share lessons learned?	Moderators: Ms. Nadiah Hanim Abdul Latif (MRDS) Mr. Sivasangaran Kumaran Dr. Carmencita Padilla (MAHPS Professor and Chancellor, University of the Philippines Manila; Founding Chairman, Philippine Society for Orphan Disorders) Ms. Jasmine Goh Chew Yin (KK Women's and Children's Hospital Singapore) Ms. Sook Yee Yoon (Genetics Counselling Society Malaysia)

Sponsored by:

AstraZeneca Janssen NOVARTIS Kyowa Kirin Roche Pfizer sanofi

Time MYT	Program	Speaker(s)
12:00PM – 1:00PM Session 3	<u>Diagnosis</u> Presentations: What are the tools and technologies that improve pathways to diagnosis? Screening and Testing – Updates in Practice • Newborn Screening Innovations across APAC • Partnerships in practice: Newborn Screening in SMA • Carrier Screening Innovation • Next Generation testing: Genomic Sequencing Discussion: How will AP Network promote diagnosis across the region?	Moderator Ms. Monica Ferrie (GSNV) Mr. Will Greene (Roche) Ms. Tara Pensa (Novartis) Dr. Alison Archibald (Mackenzie's Mission) Dr. Claudia CY Chung (Hong Kong Genome Institute)
1:00 – 2:00PM	Lunch and Networking	
2:00 – 3:30PM Session 4	<u>Patient Journey: Pathways to Diagnosis and Beyond</u> Workshop: Patients and Health Professionals – Applying learnings with "deep dive" application to different conditions (3 rotations x 20 minutes) • PKU (NBS, Diet & their therapeutic interventions • Prader Willi: Later childhood diagnosis, therapeutic interventions, progressive neurological and physical, behavioural issues • SMA: Varied experiences, some with fast progression, increasing research, therapies available, challenges to overcome • Lysosomal Storage Diseases: Varied age/stage of diagnosis, treatments available but costly • Hemophilia: Early diagnosis, treatment covered • Cystic Fibrosis: NBS, onerous management regimen, treatments but costly • Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, Kleinfelter syndrome: Invisible condition; later diagnosis affect reproduction • Amyloidosis: Adult onset, often misdiagnosed, some treatments, varied access What are learnings on accelerating pathways to accurate diagnosis to care and treatment?	Moderator Dr. Durhane Wong-Rieger (APARDO & RDI) Ms. Nadiah Hanim Abdul Latif (MRDS) Health Professional Leads Patient Support Group Leads

Sponsored by:

AstraZeneca Janssen NOVARTIS Kyowa Kirin Roche Pfizer sanofi

24-26 NOVEMBER 2023

APARDO CONFERENCE
MALAYSIA

Time MYT	Program	Speaker(s)
3:30 – 4:30PM Session 5	Feedback and Large Group Discussion Speed: How can AP Network shorten diagnostic journey with lessons learned? Scale: How can AP Network facilitate spread of shared learnings to other disease areas and countries where not yet available? Sustainability: How can AP Network address physical, knowledge, and psychological barriers among HCPs and patients; how can AP Network improve government support and pharmaceutical investment?	Moderator: Dr. Durhane Wong-Rieger (APARDO & RDI) Ms. Monica Ferrie (GSNV) Presentation: Mrs. Alexandra Heumber (RDI) - 10 min Panelists: Mrs. Alexandra Heumber (RDI) Dr. Damayanti Rusli Sjarif (Cipto Mangunkusumo National Referral Hospital, Indonesia) Dr. Ngu Lock Hock (Clinical Genetics Consultant Kuala Lumpur Hospital) Ms. Doreen Tan (Sanofi) Ms. Nadiah Hanim Abdul Latif (MRDS)
4:30 – 5:00PM	Networking & Tea	
5:00 –6:45PM	Closed Screening - Premier of UNSEEN	By MRDS & Amanda Dyer @caregiverdoc
7:00PM	Networking	

Sponsored by:

AstraZeneca Janssen NOVARTIS Kyowa Kirin Roche Pfizer sanofi

DAY 2 : Sunday, November 26 (8:30AM – 3:30PM MYT)

Time MYT	Program	Speakers
8:30 – 8:45AM	Intention Setting and Daily meditation	MRDS
9:00 – 9:15AM	Keynote Address	Dato' Dr Muhammad Radzi (Director-General of Health, Ministry of Health Malaysia)
9:15 – 10:30AM Session 1	Presentation: Innovative data platforms for patient powered databases and patient data platforms • Benefits and Risks of using real-world data & real-world evidence to optimize patient outcomes • Introduction to patient registries • MATRIX Patient Platform • Introduction to AI and Patient Data Application Discussion: Issues & Q&A • Ownership, safety, and privacy protection • Registry to Natural History Mapping • Managing, accessing, and using data to monitor therapeutic interventions	Moderator: Ms. Monica Ferrie (GSNV) Presentations (10-15 mins) Dr. Durhane Wong-Rieger (APARDO & RDI) Mr. Jason Colquitt (Across Healthcare) Ms. Andrea Rogers (Across Healthcare) Dr. Rachel Yang (CHARD) Discussion/Q&A Dr. Michelle Abadingo (University of Philippines) (TBC) Dr. Duangrurdee Wattanasirichaigoon (Mahidol University & Thai Rare Disease Foundation)
10:30 – 11:00AM	Break	
11:00 – 12:00PM Session 2	Access to Treatment – What are Rare Therapies? What are essential medicines for rare and orphan indications? What are emerging innovative therapies? • Essential medicines: IRDiRC/RDI list and WHO List of Essential Medicines • Cell and Gene therapies and other Advanced Therapeutic Products	Moderator: Dr. Durhane Wong-Rieger (APARDO & RDI) Presentations: Mrs. Alexandra Heumber (RDI) Dr. Martin Schulz (Pfizer) Discussion/Q&A Roche Representative Ms. Julie Cini (Advocacy Beyond Borders)

Sponsored by:

AstraZeneca Janssen NOVARTIS Kyowa Kirin Roche Pfizer sanofi



24-26 NOVEMBER 2023

APARDO CONFERENCE
MALAYSIA

Time MYT	Program	Speakers
12:00 – 1:00PM Session 3	Access to Treatment – Options for Funding What are Financing Options for Timely, Affordable Sustainable Access? Presentations: • Patient Engagement in Healthcare Decision-Making across AP region: HTA and Beyond (15 min) Panel Discussion: • What are Innovation Opportunities for Improving Access to Rare Disease Treatments	Dr. Durhane Wong-Rieger (APARDO & RDI) Presentations: Ms. Alison Keetley (Janssen) Ms. Harpreet Ram (GARDaccess) Discussion/Q&A Dr. Rachel Yang (CHARD) Ms. Anne Sophie Chalandon (Sanofi) Ms. Nadiah Hanim Abdul Latif (MRDS)
1:00 – 2:00PM	Lunch Break	
2:00 – 3:15PM Session 4	Connecting to Care • Hong Kong Impact of RD on Patients and Families • Role of Caregivers - Families, caregivers, healthcare professionals, community-based support • Rare Disease and Stigma • Role of RD Nurses • Patient Support Networks Mutual support models for building mental health, compassion, competence, confidence, and resilience in individuals and families	Moderator: Ms. Nadiah Hanim Abdul Latif (MRDS) Dr. Claudia CY Chung (Hong Kong Genome Institute) Ms. Jasmine Goh Chew Yin (KK Women's and Children's Hospital Singapore) Dr. Ritu Jain (DEBRA International & APARDO) Dr. Dong Dong (Illness Challenge Foundation) Ms. Jinah Kim (Korean Organization of Rare Diseases) Jee Won Choi (AstraZeneca Korea) Ms. Shakira Jamil (Spinal Muscular Atrophy Malaysia)
3:15 – 3:30PM	Conference Summary Next Steps & Closing Remarks	APARDO

Sponsored by:

AstraZeneca Janssen NOVARTIS Kyowa Kirin Roche Pfizer sanofi